Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00403-014-1464-8.

Title:
Polymorphisms in the vitamin D receptor (VDR) genes and skin cancer risk in European population: a meta-analysis | Archives of Dermatological Research
Description:
There have been a few epidemiological studies reporting VDR polymorphisms including Fok1, Bsm1, Apa1 and Taq1 with skin cancer incidence and, therefore, risk. The results, however, are controversial, often due to smaller sample size. Concerning most of the studies were performed on Caucasian population, we conducted this comprehensive analysis to better understand roles of the polymorphisms in skin cancer development among Caucasian population. The results showed that Fok1 polymorphism was associated with an overall significantly increased risk of skin cancer (Ff vs. FF: OR = 1.20, 95 % CI = 1.01–1.44; ff vs. FF: OR = 1.41, 95 % CI = 1.08–1.84; Ff + ff vs. FF: OR = 1.26, 95 % CI = 1.04–1.53). Besides, we found that Taq1 polymorphism could contribute to non-melanoma skin cancer susceptibility (Tt vs. TT: OR = 1.88, 95 % CI = 1.29–2.74; tt vs. TT: OR = 2.00, 95 % CI = 1.22–3.28; Tt + tt vs. TT: OR = 1.92, 95 % CI = 1.35–2.73). We also found that the Apa1 polymorphism is associated with skin cancer development (Aa vs. AA: OR = 1.27, 95 % CI = 1.05–1.53; Aa + aa vs. AA: OR = 1.23, 95 % CI = 1.04–1.47) and NMSC subgroup (Aa vs. AA: OR = 1.72, 95 % CI = 1.51–2.57; Aa + aa vs. AA: OR = 1.50, 95 % CI = 1.03–2.17). No significant association was observed between the Bsm1 polymorphism and skin cancer risk. The current meta-analysis shows that Fok1, Taq1 and Apa1 may be the susceptibility biomarker for skin cancer in Caucasians.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Education
  • Health & Fitness
  • Games

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We can't figure out the monetization strategy.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {šŸ”}

cancer, article, google, scholar, pubmed, vitamin, skin, cas, receptor, risk, polymorphisms, vdr, metaanalysis, gene, melanoma, polymorphism, research, apa, access, cell, privacy, cookies, content, data, population, breast, res, cutaneous, analysis, information, publish, search, genes, zhao, yang, liu, studies, fok, bsm, taq, role, prevention, variants, haussler, dermatol, european, log, journal, published, april,

Topics {āœ’ļø}

guo-hua yuĀ &Ā shu-zhen liu zhi-yong yuan basal cell carcinoma month download article/chapter current meta-analysis shows uk case–control comparisons basal cell carcinomas guo-hua yu full article pdf related subjects privacy choices/manage cookies melanoma skin cancer dermatological research aims skin cancer incidence receptor bsm1 polymorphism case–control study skin cancer risk skin cancer development article zhao published vdr data prostate cancer susceptibility bao-hong yang fok1 polymorphism meta-analysis article archives smaller sample size whitfield gk transcription factor iib bmc cancer 23 check access instant access conditions privacy policy functionally relevant polymorphisms vdr gene polymorphisms significantly increased risk cancer prevention european economic area bsm1 polymorphism cutaneous melanoma risk malignant melanoma risk accepting optional cookies receptor gene foki receptor gene cdx2 receptor gene locus jurutka pw skin cancer article log population-based study taq1 polymorphism receptor gene polymorphisms

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:Polymorphisms in the vitamin D receptor (VDR) genes and skin cancer risk in European population: a meta-analysis
         description:There have been a few epidemiological studies reporting VDR polymorphisms including Fok1, Bsm1, Apa1 and Taq1 with skin cancer incidence and, therefore, risk. The results, however, are controversial, often due to smaller sample size. Concerning most of the studies were performed on Caucasian population, we conducted this comprehensive analysis to better understand roles of the polymorphisms in skin cancer development among Caucasian population. The results showed that Fok1 polymorphism was associated with an overall significantly increased risk of skin cancer (Ff vs. FF: ORĀ =Ā 1.20, 95Ā % CIĀ =Ā 1.01–1.44; ff vs. FF: ORĀ =Ā 1.41, 95Ā % CIĀ =Ā 1.08–1.84; FfĀ +Ā ff vs. FF: ORĀ =Ā 1.26, 95Ā % CIĀ =Ā 1.04–1.53). Besides, we found that Taq1 polymorphism could contribute to non-melanoma skin cancer susceptibility (Tt vs. TT: ORĀ =Ā 1.88, 95Ā % CIĀ =Ā 1.29–2.74; tt vs. TT: ORĀ =Ā 2.00, 95Ā % CIĀ =Ā 1.22–3.28; TtĀ +Ā tt vs. TT: ORĀ =Ā 1.92, 95Ā % CIĀ =Ā 1.35–2.73). We also found that the Apa1 polymorphism is associated with skin cancer development (Aa vs. AA: ORĀ =Ā 1.27, 95Ā % CIĀ =Ā 1.05–1.53; AaĀ +Ā aa vs. AA: ORĀ =Ā 1.23, 95Ā % CIĀ =Ā 1.04–1.47) and NMSC subgroup (Aa vs. AA: ORĀ =Ā 1.72, 95Ā % CIĀ =Ā 1.51–2.57; AaĀ +Ā aa vs. AA: ORĀ =Ā 1.50, 95Ā % CIĀ =Ā 1.03–2.17). No significant association was observed between the Bsm1 polymorphism and skin cancer risk. The current meta-analysis shows that Fok1, Taq1 and Apa1 may be the susceptibility biomarker for skin cancer in Caucasians.
         datePublished:2014-04-28T00:00:00Z
         dateModified:2014-04-28T00:00:00Z
         pageStart:545
         pageEnd:553
         sameAs:https://doi.org/10.1007/s00403-014-1464-8
         keywords:
            VDR
            Fok1
            Bsm1
            Taq1
            Apa1
            Polymorphism
            Skin cancer
            Meta-analysis
            Dermatology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00403-014-1464-8/MediaObjects/403_2014_1464_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00403-014-1464-8/MediaObjects/403_2014_1464_Fig2_HTML.gif
         isPartOf:
            name:Archives of Dermatological Research
            issn:
               1432-069X
               0340-3696
            volumeNumber:306
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Xian-Zhi Zhao
               affiliation:
                     name:Tianjin Medical University Cancer Institute and Hospital
                     address:
                        name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bao-Hong Yang
               affiliation:
                     name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
                     address:
                        name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Guo-Hua Yu
               affiliation:
                     name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
                     address:
                        name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shu-Zhen Liu
               affiliation:
                     name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
                     address:
                        name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zhi-Yong Yuan
               affiliation:
                     name:Tianjin Medical University Cancer Institute and Hospital
                     address:
                        name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Polymorphisms in the vitamin D receptor (VDR) genes and skin cancer risk in European population: a meta-analysis
      description:There have been a few epidemiological studies reporting VDR polymorphisms including Fok1, Bsm1, Apa1 and Taq1 with skin cancer incidence and, therefore, risk. The results, however, are controversial, often due to smaller sample size. Concerning most of the studies were performed on Caucasian population, we conducted this comprehensive analysis to better understand roles of the polymorphisms in skin cancer development among Caucasian population. The results showed that Fok1 polymorphism was associated with an overall significantly increased risk of skin cancer (Ff vs. FF: ORĀ =Ā 1.20, 95Ā % CIĀ =Ā 1.01–1.44; ff vs. FF: ORĀ =Ā 1.41, 95Ā % CIĀ =Ā 1.08–1.84; FfĀ +Ā ff vs. FF: ORĀ =Ā 1.26, 95Ā % CIĀ =Ā 1.04–1.53). Besides, we found that Taq1 polymorphism could contribute to non-melanoma skin cancer susceptibility (Tt vs. TT: ORĀ =Ā 1.88, 95Ā % CIĀ =Ā 1.29–2.74; tt vs. TT: ORĀ =Ā 2.00, 95Ā % CIĀ =Ā 1.22–3.28; TtĀ +Ā tt vs. TT: ORĀ =Ā 1.92, 95Ā % CIĀ =Ā 1.35–2.73). We also found that the Apa1 polymorphism is associated with skin cancer development (Aa vs. AA: ORĀ =Ā 1.27, 95Ā % CIĀ =Ā 1.05–1.53; AaĀ +Ā aa vs. AA: ORĀ =Ā 1.23, 95Ā % CIĀ =Ā 1.04–1.47) and NMSC subgroup (Aa vs. AA: ORĀ =Ā 1.72, 95Ā % CIĀ =Ā 1.51–2.57; AaĀ +Ā aa vs. AA: ORĀ =Ā 1.50, 95Ā % CIĀ =Ā 1.03–2.17). No significant association was observed between the Bsm1 polymorphism and skin cancer risk. The current meta-analysis shows that Fok1, Taq1 and Apa1 may be the susceptibility biomarker for skin cancer in Caucasians.
      datePublished:2014-04-28T00:00:00Z
      dateModified:2014-04-28T00:00:00Z
      pageStart:545
      pageEnd:553
      sameAs:https://doi.org/10.1007/s00403-014-1464-8
      keywords:
         VDR
         Fok1
         Bsm1
         Taq1
         Apa1
         Polymorphism
         Skin cancer
         Meta-analysis
         Dermatology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00403-014-1464-8/MediaObjects/403_2014_1464_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00403-014-1464-8/MediaObjects/403_2014_1464_Fig2_HTML.gif
      isPartOf:
         name:Archives of Dermatological Research
         issn:
            1432-069X
            0340-3696
         volumeNumber:306
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Xian-Zhi Zhao
            affiliation:
                  name:Tianjin Medical University Cancer Institute and Hospital
                  address:
                     name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bao-Hong Yang
            affiliation:
                  name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
                  address:
                     name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Guo-Hua Yu
            affiliation:
                  name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
                  address:
                     name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shu-Zhen Liu
            affiliation:
                  name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
                  address:
                     name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zhi-Yong Yuan
            affiliation:
                  name:Tianjin Medical University Cancer Institute and Hospital
                  address:
                     name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Archives of Dermatological Research
      issn:
         1432-069X
         0340-3696
      volumeNumber:306
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Tianjin Medical University Cancer Institute and Hospital
      address:
         name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
         type:PostalAddress
      name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
      address:
         name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
         type:PostalAddress
      name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
      address:
         name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
         type:PostalAddress
      name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
      address:
         name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
         type:PostalAddress
      name:Tianjin Medical University Cancer Institute and Hospital
      address:
         name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Xian-Zhi Zhao
      affiliation:
            name:Tianjin Medical University Cancer Institute and Hospital
            address:
               name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
               type:PostalAddress
            type:Organization
      name:Bao-Hong Yang
      affiliation:
            name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
            address:
               name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
               type:PostalAddress
            type:Organization
      name:Guo-Hua Yu
      affiliation:
            name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
            address:
               name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
               type:PostalAddress
            type:Organization
      name:Shu-Zhen Liu
      affiliation:
            name:Weifang People’s Hospital, Cancer Prevention and Treatment Center
            address:
               name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
               type:PostalAddress
            type:Organization
      name:Zhi-Yong Yuan
      affiliation:
            name:Tianjin Medical University Cancer Institute and Hospital
            address:
               name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
      name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
      name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
      name:Weifang People’s Hospital, Cancer Prevention and Treatment Center, Weifang, China
      name:Key Laboratory of Cancer Prevention and Therapy, Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {šŸ”—}(113)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

3.89s.